News | June 08, 2024
Briefs: Dr. Reddy's Laboratories and Ami Organics
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Greg was also central to the planning, design, and construction of this facility
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
According to IQVIATM sales data for the 12-month period ending March 2024, the Combigan Ophthalmic Solution, 0.2%|0.5% market achieved annual sales of approximately $290.0 million
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
